Iron Toxicity Logo

For Health Care Professionals
Outside the U.S. Only

U.S. Patients

For U.S/ Healthcare Professionals

Exploratory Tests
FOR IRON OVERLOAD

Various laboratory tests have been developed to assess iron overload. While not widely available, they may hold promise of providing additional clinical information.

  • Serum ferritin iron may be less susceptible than serum ferritin to confounding factors such as inflammation (1).
  • Serum transferrin receptor concentration has been used to detect both iron deficiency and excess iron. In the presence of iron overload, cells downregulate transferrin receptor expression, and therefore serum transferrin receptor concentration would be expected to be reduced (2).
  • Labile plasma iron (LPI) quantifies the oxidative activity of the patient's plasma-borne NTBI. In theory, this test can be used as a direct measure of iron overload. One approach to measuring LPI is to measure the reactive radicals generated in the subject's blood by exposure to ascorbate, compared to those generated after the addition of a chelating agent (which blocks the oxidative activity of the NTBI) (3).
  • Directly chelatable iron (DCI) is not a test for iron overload per se, but rather an experimental assay for assaying the plasma pool of non-transferrin-bound iron (NTBI).

Print

Laboratory Tests

Exploratory tests

About Novartis Oncology

Our primary goal is to research and develop new methods to treat cancer better than is possible today.

Learn more

References

  • * (1)Herbert V, Jayatilleke E, Shaw S, et al, Serum ferritin iron, a new test, measures human body iron stores unconfounded by inflammation. Stem Cells. 1997;15(4):291-6.
  • * (2)Khumalo H, Gomo ZA, Moyo VM, et al, Serum transferrin receptors are decreased in the presence of iron overload. Clin Chem. 1998;44(1):40-4.
  • * (3)Esposito BP, Breuer W, Sirankapracha P, et al, Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood. 2003;102(7):2670-7.

Contact Us | Site Map | About Novartis Oncology | Privacy Policy

Novartis Oncology Logo

Use of this website is subject to our Terms of Use and © 2010 Novartis AG.